News

Risk factors identified for thrombosis in pediatric SLE


 

FROM LUPUS

References

Pediatric patients with systemic lupus erythematosus may have greater odds for developing thrombosis if they have a history of vasculitis, antiphospholipid antibody positivity (aPL), and/or avascular necrosis (AVN), according to Dr. Kyla Driest and her associates.

Among 974 pediatric systemic lupus erythematosus (pSLE) patients in the CARRA (Childhood Arthritis & Rheumatology Research Alliance) registry cohort who had available data on thrombosis history, 24 (2.5%) had a history of arterial thrombosis and 35 (3.6%) had a history of venous thrombosis. The researchers conducted a multivariable analysis that found statistically higher odds of thrombosis (P less than .10) among patients with histories of AVN (odds ratio, 4.24; 95% confidence interval, 1.53-11.74), aPL (OR, 2.95; 95% CI, 1.38-6.28), and vasculitis (OR, 2.19; 95% CI, 1.03-4.77), whereas significantly lower odds occurred in patients with a history of renal disease (OR, 0.47; 95% CI, 0.24-0.92). Gender and body-mass index were not statistically significant.

“This study adds to our understanding of which pSLE patients are at the most risk for thrombosis,” the researchers concluded. “These results may prompt discussion concerning potential measures to prevent thrombosis in high-risk patients.”

Find the full study in Lupus (doi: 10.1177/0961203316638164).

llaubach@frontlinemedcom.com

Recommended Reading

Inflammatory rheumatic diseases raise venous thromboembolism risk
MDedge Cardiology
VIDEO: Collaborative clinic aims at heart of CVD prevention in rheumatic diseases
MDedge Cardiology
Preeclampsia in SLE ups CVD risk
MDedge Cardiology
IPAH patients’ nonresponse to vasodilator challenge linked to poor recruitment of capillary surface
MDedge Cardiology
Catheter treatment for PAH outperforms medication
MDedge Cardiology
Uncomplicated pregnancies in women with lupus may not boost risk for CV events
MDedge Cardiology
First-line ambrisentan plus tadalafil halved PAH events
MDedge Cardiology
Riociguat deemed suitable for PAH in connective tissue disease
MDedge Cardiology
ACR: VEBs predict sudden cardiac death in systemic sclerosis
MDedge Cardiology
New tool better predicts coronary artery disease in lupus patients
MDedge Cardiology